Aspire Biopharma, Inc. (NASDAQ:PWUP)

BRIEF

published on 05/28/2025 at 14:35, 5 days 2 hours ago

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRIEF

published on 05/28/2025 at 14:35, 5 days 2 hours ago

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
PRESS RELEASE

published on 05/28/2025 at 14:30, 5 days 2 hours ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRIEF

published on 05/20/2025 at 14:35, 13 days 2 hours ago

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
BRIEF

published on 05/20/2025 at 14:35, 13 days 2 hours ago

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
PRESS RELEASE

published on 05/20/2025 at 14:30, 13 days 2 hours ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRIEF

published on 05/08/2025 at 14:05, 25 days 3 hours ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRIEF

published on 05/08/2025 at 14:05, 25 days 3 hours ago

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
PRESS RELEASE

published on 05/08/2025 at 14:00, 25 days 3 hours ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma
BRIEF

published on 04/29/2025 at 14:35, 1 month 3 days ago

Aspire Biopharma reçoit l'approbation du comité d'éthique de la recherche (IRB) pour un essai sur l'aspirine à action rapide

Essai Clinique Procédure Accélérée De La FDA Aspirine Sublinguale Approbation De L'IRB Pharmacocinétique

1 2 ... 5

Published on 06/02/2025 at 15:00, 2 hours 23 minutes ago

Newsmax to Participate in Maxim Group's "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Virtual Conference
Published on 06/02/2025 at 15:00, 2 hours 23 minutes ago

1933 Industries Announces the Completion of the Purchase of 9% Interest of Cultivation and Production Subsidiary
Published on 06/02/2025 at 14:55, 2 hours 28 minutes ago

Tectonic Metals Launches Largest Drill Program to Date with Three Drill Rigs at Flat Gold Project, Alaska
Published on 06/02/2025 at 14:35, 2 hours 48 minutes ago

Sekur Private Data Ltd. Announces Newly Constituted Strategic Advisory Board - Appoints Jill Kelley as Chair of the Board
Published on 06/02/2025 at 14:30, 2 hours 53 minutes ago

Appointment of Nicholas Holthouse as President & CEO

View all ACCESSWIRE

Published on 06/02/2025 at 16:11, 1 hour 11 minutes ago

Original-Research: CR Energy AG (von First Berlin Equity Research GmbH): Under Review
Published on 06/02/2025 at 16:00, 1 hour 22 minutes ago

Total Voting Rights
Published on 06/02/2025 at 15:59, 1 hour 23 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 06/02/2025 at 15:58, 1 hour 24 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 06/02/2025 at 15:56, 1 hour 26 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dalata Hotel Group plc

View all EQS

Published on 05/30/2025 at 22:00, 2 days 19 hours ago

Information sur les comptes annuels
Published on 05/30/2025 at 22:00, 2 days 19 hours ago

Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 2 days 23 hours ago

Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 4 days 18 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 4 days 18 hours ago

Engagements collectifs de conservation de titres de la société

View all LES ECHOS COMFI WIRE

News